David Sinclair’s Longevity Protocol — 2026 Synthesis
TL;DR
- Sinclair’s 2026 stack is a quieter, less-pharmaceutical version of his 2023 stack: still NMN + resveratrol as the SIRT1/NAD core, still berberine/metformin for glucose, but rapamycin has dropped from weekly to roughly four times a year and several 2023-era additions (taurine, TMG) have been quietly removed.
- The biggest 2023→2026 reversal: he now downplays rapamycin after epigenetic-aging clocks failed to show an effect, and prioritizes glucose control (HbA1c, fasting, acarbose, metformin/berberine) as the dominant lever. He also added nattokinase (10,000 units/day) for arterial plaque, tracked via carotid IMT ultrasound rather than CT (his lab argues medical radiation accelerates aging).
- For a healthy 30-something founder like Ben, almost none of this is “evidence-strong enough to copy as-is.” The protocol is heavily entangled with companies Sinclair owns or advises (MetroBiotech / NMN, Tally Health, Life Biosciences), and the broader longevity-research community — Peter Attia, Brad Stanfield, Rich Miller — has publicly classified large pieces of it (resveratrol, the NMN-as-life-extender story) as marketing rather than science.
Protocol details
Supplements (with dose, time of day, with/without food, his stated rationale)
| Supplement | Dose | Timing | Stated mechanism |
|---|---|---|---|
| NMN (nicotinamide mononucleotide) | ~1 g | Morning, with yogurt | NAD+ precursor; NAD+ declines with age; sirtuin (SIRT1) substrate. Sinclair co-founded MetroBiotech around this molecule. |
| Resveratrol | ~1 g | Morning, mixed with fat (yogurt) for absorption | Claimed sirtuin (SIRT1) activator; he ties sirtuins into the Information Theory of Aging that underpins his reprogramming work. Hydrophobic — must take with fat. |
| Berberine | ~1 g | Daily | AMPK activator, glucose-lowering. Replaced his daily metformin around 2025 because metformin “was hard on his stomach.” |
| Metformin | 1 g (or skipped) | Occasional, not daily | Glucose-lowering; AMPK activator. He still names it but admits he no longer takes it daily. |
| Rapamycin | ~5–6 mg | ~4 times per year (per June 2025 Diamandis interview) | mTOR inhibitor. Down-prioritized after he reports rapamycin failed to move epigenetic-age clocks while fasting / acarbose / metformin did. |
| Nattokinase | 10,000 fibrinolytic units | Daily, 12+ months | Claimed to reverse arterial plaque per RCTs he cites; he tracks via carotid IMT ultrasound. |
| Vitamin D3 | ~4,000–5,000 IU | Daily | Standard immune / metabolic baseline. |
| Vitamin K2 | Standard dose | Daily, paired with D3 | Calcium trafficking — keeps calcium in bone, out of arteries. |
| Fisetin | ~500 mg | Periodic / monthly pulse | Senolytic — clears senescent cells (mouse-strong evidence, human-thin). |
| Spermidine | 1–2 mg | Daily | Autophagy inducer. |
| Alpha-lipoic acid | ~300–500 mg | Daily | Antioxidant; mitochondrial cofactor. |
| Fish oil (omega-3) | Standard dose | Daily | Cardiovascular / inflammation. |
| CoQ10 | Standard dose | Daily | Mitochondrial cofactor (and a hedge against statin-related depletion). |
| Low-dose aspirin | 81 mg | Daily | CVD risk reduction. |
| Statin | ~80 mg (high) | Daily | LDL lowering — he is on a high-dose statin. |
| Removed since 2023: taurine, TMG (trimethylglycine) | — | — | Dropped 2025; taurine was added during the 2023 hype, dropped after the longevity signal didn’t hold. |
Lifestyle (diet, exercise, sleep, fasting, cold/heat, light)
- Diet: mostly vegan, plant-forward, low-sugar. Credits his wife Serena Poon for the dietary overhaul. Says he gained ~2 additional years of biological-age reversal from the plant-based switch (self-reported via biological-age testing).
- Fasting / eating window: ~6-hour eating window most days, skips breakfast. Frames it as practical caloric restriction / mTOR-pulsing.
- Alcohol: quit. Cites the “even one drink/day correlates with smaller brain volume” evidence.
- Exercise: moderate — described publicly as Zone 2 + resistance, not extreme. Less of a focus in his messaging than diet/glucose.
- Sleep / stress: meditation practice (also via Serena), described as the intervention that broke his Type-A rumination.
- Social: flags loneliness as a mortality multiplier; “get a pet, get a partner” closer in the 2026 episode.
- Imaging: prefers carotid intima-media thickness (IMT) ultrasound over CT; he claims his lab has shown medical radiation accelerates aging.
- Glucose tracking: continuous glucose monitor; treats HbA1c as a primary biomarker. Diamandis adds Fountain Life data (uncorroborated cohort) claiming HbA1c outranks LDL and Lp(a) as the top CVD predictor.
What he’s CHANGED his mind on (2023 → 2026)
- Rapamycin: weekly → ~4x/year. In 2023 he publicly described 5–6 mg weekly. By the June 2025 Diamandis interview he had pulled way back, saying epigenetic-aging clocks didn’t move on rapamycin while fasting, acarbose, and metformin did. This is a real walk-back, not a re-framing.
- Metformin: daily → occasional, mostly replaced by berberine. Stated reason is GI side effects, not loss of belief in the mechanism.
- Taurine: added 2023, dropped 2025. Followed the hype cycle in and out. Notable because he was a public advocate during the 2023 Science paper run-up.
- TMG: dropped. Was an NMN-pairing supplement in earlier stacks.
- Nattokinase: added. Claims it’s the only molecule shown in 1000+ subject RCTs to reverse arterial plaque. The strength of that claim is contested.
- Imaging stance hardened: explicitly avoids CT now, preferring carotid IMT ultrasound on the radiation-accelerates-aging claim.
- Tone on partial reprogramming: in 2023 he said “a few years away;” in 2026 he says the first OSK in-human trial is “days away” via Life Biosciences (eye / glaucoma indication). Either 2026 produces a real readout or the timeline slips again.
Caveats
Sinclair commercial conflicts
Every major recommendation overlaps with a company he profits from. He acknowledges the optics (“I suffer from my face showing up on people’s websites selling products”) but does not pull the recommendations.
- MetroBiotech — NMN pharmaceutical company, spun out of his lab. He recommends NMN.
- Life Biosciences — running the OSK partial-reprogramming eye trial. He is the public face of OSK.
- Tally Health — biological-age testing (epigenetic clocks), direct-to-consumer. He recommends biological-age testing.
- InsideTracker — advisor / investor; recommends biomarker testing.
- Friends of Sinclair Lab (FoSL) — private membership funding ~$6M/year of his Harvard lab after federal grants were cut; the 2026 podcast doubles as a fundraising pitch.
- Sirtris / GSK history — GSK acquired Sirtris (Sinclair’s resveratrol company) for $720M in 2008 and later shut the program down after failing to reproduce key results. Worth knowing before assuming his resveratrol thesis is consensus.
Where the science is contested
- Resveratrol: Peter Attia categorizes it as “nonsense” for life/healthspan extension. Brad Stanfield, Andrew Huberman, and Attia have all moved off it. Bioavailability in humans is extremely low; GSK’s $720M Sirtris bet collapsed. The Sinclair sirtuin-activation story has not held up in independent replication at the strength he initially claimed.
- NMN / NR (NAD+ precursors): human trials are conflicting. Rich Miller (running the NIA Interventions Testing Program) has not produced lifespan extension in mice on NR; NMN is partially more bioavailable but still lacks strong clinical endpoints. Peter Attia’s read: support is “almost entirely theoretical.” Sinclair’s MetroBiotech is in phase 2 — not yet a positive readout.
- Telomerase activation / “backup copy” framing: the metaphor oversimplifies epigenetic biology and is not how most aging biologists describe the mechanism.
- Rapamycin off-label for healthy people: real evidence base in lab mice, but the human dose-response, frequency, and side-effect profile (immune suppression, glucose tolerance) are unresolved. Sinclair’s own walk-back from weekly to quarterly is itself a data point.
- Metformin in non-diabetics (TAME trial): still pending; current evidence is association-level, not causal for healthy people. Some studies suggest metformin blunts exercise adaptation in healthy adults — a real cost.
- Nattokinase plaque reversal: the “1000+ subject RCTs” claim is stronger than the published literature actually supports; the trials are smaller, mostly Asian cohorts, with mixed endpoints. Worth a vault cross-check before treating as established.
- HbA1c > LDL/Lp(a) as #1 CVD correlate: this is Diamandis’ Fountain Life cohort claim, not population-scale published evidence. Fountain Life is a self-selected concierge cohort; both Diamandis and Sinclair benefit from a glucose-monitoring-first narrative.
- OSK partial reprogramming: published in Nature 2020 in mice. The 2026 in-human eye trial is the first real test. Pre-readout, treat the timeline claims as marketing.
Says-vs-does gap
Sinclair has historically been a precise scientist on stage and a looser brand voice in interview format. The 2026 Diamandis episode is closer to brand voice — fundraising for FoSL, Abundance Summit framing, hardware-store-grade claims like “no biological upper limit on lifespan.” The published-paper Sinclair and the podcast Sinclair are not always the same person; weight his claims accordingly.
How this maps to Ben’s situation
Context: 30-something founder, generally healthy, wears a Whoop, no known chronic conditions, no diabetes risk flagged. The question isn’t “should I copy Sinclair’s protocol” but “which 10% of this is signal.”
Evidence-strong enough to copy (lifestyle, not pharmaceuticals)
These are the Sinclair recommendations where he’s downstream of broad scientific consensus, not driving it:
- Mostly plant-forward, low-sugar, real-food diet. Generic longevity-medicine consensus, not a Sinclair-specific bet.
- 6–8 hour eating window / skip breakfast. Modest evidence for metabolic markers; low downside; cheap to try.
- No (or minimal) alcohol. The brain-volume / cancer-risk evidence is solid and isn’t Sinclair-specific.
- Vitamin D3 + K2. Standard, cheap, well-tolerated. Worth a 25-OH vitamin D blood test first to dose properly.
- Omega-3 (fish oil) at therapeutic dose. Supported by independent literature, not a Sinclair bet.
- Zone-2 cardio + resistance training. Universal longevity-medicine consensus.
- Sleep hygiene / stress reduction (meditation). Universal.
- Social connection as a mortality multiplier. Universal.
That’s eight items. None of them require Sinclair to be right.
Bloodwork-first before considering
Do NOT start these without a baseline panel. Most need a real PCP or longevity-medicine doc.
- Metformin / berberine for glucose: requires fasting glucose, HbA1c, ideally a CGM trial first. If HbA1c is in the optimal range (sub-5.4) at age 30-something, the case for daily metformin is essentially zero, and metformin may blunt training adaptation.
- Statin (especially high-dose): requires lipid panel + Lp(a) + ApoB. Sinclair takes a high-dose statin; the right dose for Ben is whatever the numbers say, not whatever Sinclair takes.
- Low-dose aspirin: USPSTF has de-recommended primary-prevention aspirin in healthy adults under 60 due to bleeding risk. Don’t start without an MD.
- Rapamycin: prescription only, real immune/metabolic side effects, requires a longevity-medicine doc willing to prescribe off-label and monitor.
- Nattokinase: anticoagulant effects; ask before stacking with aspirin or any antiplatelet.
Low-priority for a healthy 30-something
These are aimed at chronic-disease patients or 60+ adults staring down healthspan compression. Not for Ben right now.
- OSK gene therapy / partial reprogramming. The first in-human trial is for blindness/glaucoma, not healthy adults. Track for 2026 readout; don’t try to access.
- NMN at $$ doses. The human evidence is thin and Sinclair has direct financial interest. If Ben wants to bet on it, treat it as a cheap experiment with a clear pre-registered biomarker, not a forever-stack item.
- Resveratrol. Attia, Stanfield, and Huberman have all dropped it. Bioavailability problems are well-documented. Skip unless new evidence emerges.
- High-frequency biological-age testing (Tally Health etc.). Test-retest noise is high relative to the effect sizes any intervention is going to move. Annual at most; don’t chase the number.
- Fisetin senolytic pulses. Mouse-strong, human-thin. Optional curiosity experiment.
- Spermidine. Cheap, low-evidence; if you eat plenty of mushrooms / aged cheese / wheat germ you get it dietarily.
The actually-useful Sinclair takeaways for Ben
If we strip away the supplement marketing, the load-bearing nutrients of Sinclair’s worldview that are worth internalizing:
- Metabolic health is the dominant lever. Glucose control, HbA1c, insulin sensitivity, visceral fat — these matter more than any specific supplement. Whoop + a one-time CGM trial would teach more than a year of NMN.
- Most aging is information loss / epigenetic, not damage. This is a useful mental model regardless of whether OSK delivers.
- Imaging-first instead of guessing. Carotid IMT ultrasound, a coronary calcium score (CAC) once at 40, ApoB-based lipid management. Do not extrapolate from age 35 — measure.
- Track the biomarkers that actually move with intervention, not the ones a $499 panel sells you.
Sources cited
Vault
- 2026-04-27-moonshots-sinclair-longevity-pill — Moonshots EP #249, April 2026, full assessment with bias flags
- 2023-08-24-moonshots-ep60-david-sinclair-aging-optional — Moonshots EP #60, August 2023 baseline
06-reference/transcripts/2022-12-29-moonshots-sinclair-ama-age-reversal-transcript.md— December 2022 AMA transcript
Web (May 2026 search; non-paywalled summaries)
- BodySpec — David Sinclair Supplements: 2026 Protocol & Guide: https://www.bodyspec.com/blog/post/david_sinclair_supplements_2026_protocol_guide
- omre — David Sinclair Supplement Routine 2026: https://omre.co/blogs/news/david-sinclair-supplements
- CoreStacks — Sinclair’s Stack Changes 2020 to 2026: https://corestacks.com/david-sinclair-supplement-changes-2026/
- NOVOS Labs — David Sinclair Supplements 2026 List & Dosage: https://novoslabs.com/blog/supplements/david-sinclair-supplements-list/
- Brainflow — David Sinclair’s Supplement List 2026 The Complete Protocol: https://brainflow.co/dr-david-sinclairs-supplement-list-for-longevity/
- Diamandis Metatrends — Updated Longevity Protocols for 2026: https://metatrends.substack.com/p/updated-longevity-protocols-for-2026
- NMN.com — Peter Attia’s Stance on Touted Longevity Interventions: https://www.nmn.com/news/peter-attias-stance-on-popular-geroprotective-interventions-rapamycin-metformin-resveratrol-and-fasting
- Peter Attia MD — Does NMN improve metabolic health in humans?: https://peterattiamd.com/does-nmn-improve-metabolic-health-in-humans/
- nad.com — Attia and Rich Miller on resveratrol: https://www.nad.com/news/revolutionary-breakthrough-or-just-hype-dr-peter-attia-and-aging-expert-dr-rich-miller-expose-the-truth-behind-popular-anti-aging-compounds
Related
- founder-longevity-stack
- brain-health
- cross-check
- Sanity-Check-Data-Dots